The blood donor history questionnaires are designed to aid blood establishments in evaluating a prospective donor’s history relative to current known blood safety risks, FDA regulations and recommendations, and AABB Standards. The Full-Length Donor History Questionnaire (DHQ) is designed to evaluate any donor, while the Abbreviated Donor History Questionnaire (aDHQ) can be used with qualified frequent blood donors.
There are five documents in each set, whether the Full-Length (DHQ) or Abbreviated (aDHQ) version:
Questionnaire – a list of broad capture questions to be answered by the donor
Educational Materials – information required by FDA or AABB to be provided to the donor prior to answering the Questionnaire
Medication Deferral List – a list of medications required by FDA or AABB to be used in the donor’s evaluation prior to or while answering the Questionnaire
User Brochure (UB) – instructions for blood establishment staff on how to use all the materials in evaluating a donor’s eligibility to donate blood, as well as maintenance of and revisions to the materials.
vCJD Countries of Risk – a list of countries used by the donor while answering questions on the DHQs and by the donor historian to identify risk of vCJD transmission according to current recommendations in FDA guidance
Flowcharts – optional resource to aid blood establishment staff in completing the interview process
References – a list of relevant documents used in the development of the DHQs and accompanying materials
The version 2.0 Blood Donor History Questionnaires and Accompanying Materials were
officially recognized by the FDA in
Guidance, May 27, 2016. FDA and AABB consider v2.0 to be the current version of the AABB DHQ/aDHQ materials that replaced v1.3 DHQ and materials.
The change tables, found under the “Supporting Documents” tab, are intended to help blood centers identify significant revisions made during the review process. Blood centers are responsible for preparing accurate DHQs and accompanying materials, prior to implementation, that are consistent with FDA-recognized version 2.0 documents.
Those with questions regarding the version 2.0 documents may contact AABB at